The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2015Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement
Study Rationale:
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in... -
Therapeutic Pipeline Program, 2014Development of a mGluR4 Therapeutic for Parkinson's Disease
Study Rationale:
One of the major objectives for the development of new treatments for Parkinson’s disease is to find alternatives to the stimulation of the dopaminergic system through levodopa and... -
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Using Risk Scores to Link Molecular Mechanisms to Clinical Outcomes in Parkinson's Disease
Study Rationale:
The symptoms and course of Parkinson’s disease (PD) show remarkable variation from one person to another, indicating differences in the underlying disease process that may also be... -
, 2021Evaluating Patient-reported Outcome Assessment in Early Parkinson’s Disease
Study Rationale: There are currently no validated tools for assessing functional changes in people at the earliest clinical stages of Parkinson’s disease (PD). Available approaches lack sufficient...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using “Nanobodies” to Prevent Formation of Intracellular Alpha-synuclein Aggregates
Study Rationale: The aggregation of a structurally abnormal form of the protein alpha-synuclein appears to be responsible for the initiation and progression of Parkinson’s disease (PD). In previous...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.